Please assess the completion status of the following clinical trial:

Trial Title: Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age ≥ 18 years) patients,~* Having clinical indication for placement of a single PVC for at least 48 hours (no minimum port access during the study duration),~* Willing and able to provide informed consent.~Exclusion Criteria:~* Known allergies to CHG, PVI, isopropanol or ethanol,~* Participation to another clinical trial aimed at reducing PVC complications,~* Suspicion of bloodstream infection at catheter insertion,~* Skin injury a catheter insertion site increasing the risk of catheter infection,~* PVC inserted extremely urgently, making it impossible to comply with the protocol,~* Intravascular catheter in place within the last 2 days, or within the last 2 weeks and with local signs of catheter complication,~* Difficult catheter insertion suspected (obesity, known IV drug users, non-visible venous network after placement of a tourniquet...),~* Patients already enrolled in this study,~* Terminal or moribund patient not expected to live more than one week,~* Patients not benefiting from a Social Security scheme or not benefiting from it through a third party,~* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.~* Pregnant or breastfeeding women~* Women at age to procreate and not using effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVI et Insyte (Type: ACTIVE_COMPARATOR): Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD
- CHG et Insyte (Type: EXPERIMENTAL): Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD
- PVI et Nexiva (Type: EXPERIMENTAL): Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
- CHG et Nexiva (Type: EXPERIMENTAL): Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD

Based on this trial design, predict the completion outcome and termination type (if applicable).